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REVIEWS AND COMMENTARY • STATE OF THE ART
Strategies for the diagnosis and treatment of biliary strictures continue to evolve with advancements in 
minimally invasive options offered by radiologists and 
endoscopists. Over the past decade, advancements in 
imaging technology have improved diagnostic accuracy 
and have paved the way for more precise application of 
multidisciplinary treatment options. The Holy Grail in 
the management of both benign and malignant stric-
tures is to achieve permanent patency and minimize the 
need for repeated interventions or surgical procedures. 
For benign strictures, newer approaches, such as large-
bore catheterization, cutting-balloon dilation, and place-
ment of retrievable covered stents, have demonstrated 
improved results when compared with those of previous 
approaches, and investigational strategies, such as place-
ment of resorbable stents, are promising. For unresect-
able malignant strictures, the palliative goal of achieving 
patency that exceeds survival is possible in some patients 
via placement of permanent uncovered, partially cov-
ered, or completely covered stents. However, in many 
patients, internal stents are occluded due to in- or over-
growth of the tumor; these patients require reinterven-
tion. Palliation that also improves patient survival may be 
achievable with covered stents and with developing tech-
nologies, such as drug-coated balloons and intraductal 
radiofrequency ablation. Despite improvements in endo-
scopic management, such as double-balloon enteroscopy 
and US-guided sharp-puncture techniques, radiologists 
continue to play a critical role in the management of bili-
ary strictures by applying advanced imaging techniques to 
enable diagnosis and guide tissue sampling and by using 
advanced percutaneous treatment options when endo-
scopic options fail or are not feasible. In this article, we 
review the current state of technology in the diagnosis 
and treatment of biliary strictures and discuss the role of 
radiologists in the context of the latest multidisciplinary 
advancements.
Etiology
Biliary strictures can be broadly classified as benign or ma-
lignant biliary strictures (MBSs). Benign biliary strictures 
(BBSs) have various origins, each with a different natural 
history and each demonstrating a different response to 
treatment (1). Iatrogenic causes, such as cholecystectomy 
and orthotopic liver transplantation, are the most com-
mon causes of BBS. Postoperative biliary strictures can 
be further classified as anastomotic or nonanastomotic. 
Other causes include inflammatory, autoimmune, or 
immunoglobulin G4–related cholangiopathy; radiation-
induced sclerosing cholangitis; ischemia; and infections 
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(Table 1) (1,2). MBSs usually result from local malignancy, 
most commonly cholangiocarcinoma, pancreatic adenocarci-
noma, liver metastases, hepatocellular carcinoma, ampullary 
carcinoma, or gallbladder adenocarcinoma. Other causes can 
include lymphoma and metastasis to the regional lymph nodes 
(3).
Classifications
The Bismuth classification is the most commonly used classi-
fication for BBSs and MBSs due to hilar cholangiocarcinoma. 
The Bismuth classification is based on the location of the stric-
ture and is used to help surgeons identify the biliary level for 
repair and anastomosis (4). Type I strictures are located more 
than 2 cm distal to the confluence of the left and right hepatic 
ducts, and type II strictures are located less than 2 cm from 
the hepatic confluence. Type III strictures involve the hepatic 
confluence but do not affect its patency, and type IV strictures 
involve the confluence and interrupt it. When a stricture in-
volves the aberrant right sectoral hepatic duct alone or with 
concomitant injury of the common hepatic duct, it is consid-
ered a type V lesion.
Another commonly used classification, the Strasberg clas-
sification, was originally described for laparoscopic injuries of 
the biliary ducts. The Strasberg classification system also takes 
the presence of a bile leak and lateral injuries into consideration 
(Table 2) (5,6).
Clinical Presentation
Clinical symptoms of biliary obstruction include jaundice, 
pruritus, and darkened urine from renal excretion of biliru-
bin. Generalized symptoms, such as weight loss, fever, nau-
sea, vomiting, and malaise, also may be noted and depend on 
the underlying cause. In advanced cases, biliary obstruction 
can lead to ascending cholangitis, gram-negative septicemia, 
and hepatic abscesses. In patients with malignant biliary ob-
struction (MBO), distal obstruction prevents ascending chol-
angitis in most patients, and duct dilatation at presentation 
may be marked despite the absence of fever or leukocytosis. 
Early detection is uncommon because screening relies on 
clinical symptoms, which are often nonspecific and minor, 
despite the presence of disease too extensive for curative re-
section. In such patients, treatment strategies involve percu-
taneous and endoscopic endobiliary procedures for palliative 
decompression.
Imaging Diagnosis of Biliary Strictures
Invasive imaging modalities, such as percutaneous transhe-
patic cholangiography (PTHC) (Fig 1) are usually preceded 
by noninvasive options to diagnose and characterize biliary 
strictures. These options, which are briefly summarized in 
Table 3, include US (7) (Fig 2), multidetector CT (8–16), 
and MRI with MR cholangiopancreatography (17–24). 
While reported accuracy rates for characterization of stricture 
extent with multidetector CT are lower than those reported 
for MRI, more recently, intraprocedural cone-beam CT has 
proven to be useful in three-dimensional characterization of 
biliary strictures and occlusions before percutaneous or sur-
gical reconstruction of the biliary-enteric anastomosis (Fig 
1). A detailed description of the application of these tools is 
available in Appendix E1 (online).
Percutaneous Transhepatic Cholangiography
PTHC and endoscopic retrograde cholangiopancreatography 
(ERCP) offer the means to perform fluoroscopic imaging, tis-
sue sampling, and therapeutic management of obstruction. 
Unlike ERCP, PTHC requires creation of a parenchymal 
tract and is typically performed once the decision to perform 
biliary drainage has been made based on clinical presentation 
and cross-sectional imaging findings. The decision to perform 
PTHC using a right- or left-sided approach depends on the 
location of the biliary stricture (right or left side of the bili-
ary tree) (Fig 2). In the left-sided approach, access to the bili-
ary system is typically obtained with US guidance (Fig 3). For 
biliary strictures located in the common hepatic duct or the 
common bile duct, most interventional radiologists prefer to 
use the right midaxillary approach, as the majority of the liver 
is drained by the right-sided ductal system, and the right-sided 
approach is associated with lower complication rates.
In addition to acute hemorrhage, other rare complications 
of PTHC and biliary drainage include pneumothorax, hemo-
thorax, injury of the gallbladder, or a combination of these 
three (7,25). The reported rates of major complications, such 
as sepsis, acute hemorrhage, pneumothorax, and mortality, are 
0.5%–2.5% (26,27).
Abbreviations
BBS = benign biliary stricture, CSEMS = covered SEMS, EBD = endo-
scopic biliary drainage, ERCP = endoscopic retrograde cholangiopan-
creatography, MBO = malignant biliary obstruction, MBS = malignant 
biliary stricture, PTBD = percutaneous transhepatic biliary drainage, 
PTHC = percutaneous transhepatic cholangiography, SEMS = self-
expanding metal stent, USEMS = uncovered SEMS
Summary
This article reviews state-of-the-art minimally invasive techniques 
used to manage biliary strictures.
Essentials
 n Intraprocedural cone-beam CT can be useful in three-dimensional 
characterization of biliary strictures and occlusions before percuta-
neous or surgical reconstruction of the biliary-enteric anastomosis.
 n Biodegradable stents may represent an interesting treatment op-
tion for benign biliary strictures, potentially offering not only bet-
ter technical results but also a better quality of life for patients.
 n When self-expanding metal stents are placed via a percutaneous 
approach, placement of an internal-external biliary drain for  
1–2 weeks enables easy interval management of complications, 
such as bleeding and acute reobstruction; this option represents 
an advantage of percutaneous transhepatic biliary drainage over 
endoscopic biliary drainage, as it provides additional opportunities 
to clear clots and debris and to replace stents in problem segments 
before complete removal of the catheter.
 n Palliative treatment of symptoms of inoperable malignant biliary 
strictures continues to be the main application of percutaneous 
and endoscopic management; most practitioners tailor the use of 
covered self-expanding metal stents and uncovered self-expanding 
metal stents on a patient-by-patient basis to provide an option that 
is clinically effective, avoids unnecessary secondary procedures, 
and is cost effective.
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resulting in bile leakage. In such pa-
tients, the general recommendation is to 
leave an internal-external percutaneous 
transhepatic biliary drainage (PTBD) 
in place for at least 2 weeks before at-
tempting balloon dilation (2,25).
When balloon dilation is per-
formed, the balloon should have a di-
ameter at least as large as the caliber of 
the proximal and distal bile ducts; the 
balloon can also be oversized by up to 
25%–30% of this diameter and, ide-
ally, should be inflated in the middle 
of the stricture (2,39,40). Once suc-
cessful balloon dilation has been per-
formed (20%–30% residual stenosis and spontaneous contrast 
material passage), an internal-external biliary drain should be 
left in place for at least 2–4 weeks. Some authors prefer small-
caliber drainage catheters (12 F or smaller) (41), while others 
prefer larger catheters (18–20 F) that are left in place longer 
(.6 months) to achieve stricture remodeling (42).
Percutaneous balloon dilation of biliary strictures was first 
reported in the 1970s and 1980s, with initial studies reporting 
3-year patency rates of 38%–67% (43–45). In a series of 75 pa-
tients who underwent balloon dilation for benign biliary stenosis 
over a 30-year period, Cantwell et al (41) reported 100% techni-
cal success and 75% successful management during follow-up. 
In this series, 30.6% of patients required two to four treatments. 
The probability of not having clinically important stricture re-
currence at 5 years was 52% after the first treatment and 43% af-
ter the second treatment. In the same series, major complications 
occurred in four of 205 procedures (2%); these complications 
included two subphrenic abscesses, one hepatic arterial pseudoa-
neurysm, and one event of hemobilia treated with transfusion. 
In a retrospective series of 98 patients with BBS treated with 
balloon dilation and long-term (minimum 3 months) drainage, 
Technical details of PTHC and the diagnostic advantages of 
ERCP, PTHC (28–33), and additional modalities, such as PET 
and intraductal US (34–38), are summarized in Appendix E1 
(online).
Management of BBSs
Several techniques are available to treat BBS; they include bal-
loon dilation, percutaneous biliary drain placement, and stent 
placement. Although interventional radiologists have been in-
volved in the management of BBS for years, no strong con-
sensus exists regarding the ideal technique with which to treat 
BBS.
Balloon Dilation
Once the stricture has been crossed, the interventional radiolo-
gist must decide whether to perform balloon dilation. Particu-
lar attention should be paid to patients with early (,1 month) 
postoperative bilioenteric anastomotic stricture, as the stricture 
might be due to edema or a kink at the site of stricture; in such 
cases, balloon dilation would be ineffective. Furthermore, bal-
loon dilation might damage a fresh anastomosis, potentially 
Table 1: Etiology of Biliary Strictures
Type of Disease Description
Benign
Iatrogenic Postendoscopic sphincterotomy, posthepatobiliary surgery
Inflammatory Primary and secondary sclerosing cholangitis, acute or chronic pan-
creatitis
Ischemic Hepatic artery stenosis or thrombosis
Infectious Recurrent pyogenic cholangitis, human immunodeficiency virus  
cholangiopathy, tuberculosis, sarcoidosis, parasitic, choledocholithiasis
Autoimmune Immunoglobulin G4 cholangitis
Miscellaneous Portal biliopathy, trauma, papillary stenosis
Malignant
Cholangiocarcinoma Involving intra- and extrahepatic bile ducts
Carcinoma in the head of the pancreas, ampullary or  
duodenal malignancies
Distal common bile duct stricture
Carcinoma in the gallbladder Invading the biliary ducts
Lymphoma and metastatic lymphadenopathy Compressing biliary ducts
Intrahepatic metastases Invading or compressing biliary ducts
Table 2: Strasberg Classification System for Bile Duct Injuries
Type Description
A Leak from the cystic duct or a small duct in the liver bed
B Occlusion of an aberrant right hepatic duct
C Transection of an aberrant right hepatic duct without ligation
D Lateral injury to a major bile duct
E1 Distal CHD stricture with a CHD stump ≥ 2 cm long
E2 Proximal CHD stricture with a CHD stump , 2 cm long
E3 Hilar stricture with no CHD stump but with preservation of the hilar confluence
E4 Hilar stricture with loss of communication between the right and left hepatic ducts
E5 Aberrant right hepatic duct stricture with or without concomitant CHD stricture
Note.—Adapted, with permission, from reference 5. CHD = common hepatic duct.
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catheters maintained in place 
for 6–12 months. This tech-
nique was initially proposed 
in the 1970s by Ring et al (48) 
and is still endorsed by some 
authors as a successful way to 
reduce the restenosis rate. In a 
recent study, Ludwig et al (49) 
used this treatment strategy in 
47 patients who underwent 
placement of a 10-F catheter 
across the stricture. The cath-
eter was subsequently upsized 
every 1–2 weeks, until a size 
of 18–20 F was reached. This 
large catheter was left in place, 
with subsequent maintenance, 
for at least 6 months. At a 
mean follow-up time of 20.3 
months, primary patency rates 
were 81.25% in patients who 
had previously undergone liver 
transplantation and 89.5% in 
the remaining patients. How-
ever, 11 patients in the series 
(23.5%) were not able to com-
plete the treatment course, and 
three had treatment-related 
complications, including one 
intraprocedural injury to the 
hepatic artery, one Roux limb 
perforation during upsizing, 
and one event of pain at the 
drainage site (this patient opted 
out of further treatment). De-
Pietro et al (50) reported a similar approach when using 18-F 
catheters in 71 patients. Kaplan-Meier analysis in this study 
showed stricture patency probabilities of 84%, 78%, 74%, and 
67% at 1, 2, 5, and 10 years after treatment, respectively.
A different strategy based on the same concept was proposed 
by Gwon et al (51). With this proposed dual-catheter place-
ment technique, an 8.5-F catheter is advanced into a 14-F 
catheter and then out of the catheter via a side hole so that the two 
catheters run parallel at the level of the stricture, reaching a total 
of 22.5 F. With this technique, Gwon et al reported primary 
patency rates of 96%, 92%, and 91% at 1, 2, and 3 years, respec-
tively. Recurrence was reported in seven (9%) of the 78 patients 
at a mean of 15.4 months 6 8.9 (standard deviation).
Stent Placement
Stent placement is another treatment option for BBSs. In 
particular, the use of retrievable covered self-expanding metal 
stents (CSEMSs) has been proposed as a possible treatment 
strategy on the basis of (a) the higher expansion force and 
larger diameter of these stents versus those of indwelling cath-
eters and (b) their sustained dilation effect (52,53). These 
stents are generally covered by a polytetrafluoroethylene layer 
Janssen et al (46) reported 13 unsuccessful procedures (13.3%) 
that required surgical intervention. In the same series, another 
four patients required surgery for restenosis that developed after 
treatment.
When repeated standard balloon dilation attempts fail, use 
of a cutting balloon has been reported to be feasible and safe, 
with improved results when compared with those attained with 
standard balloon dilation (47). Cutting balloons have four long 
blades attached to the balloon and might be effective in the treat-
ment of recalcitrant restenosis, in which subsequent balloon di-
lations might have resulted in more focal fibrosis and scarring. In 
a series of 22 patients who had undergone liver transplantation 
and who then underwent 49 cutting balloon dilations, Saad et al 
(47) reported primary success rates of 100% for primary stenosis 
and 90% for restenosis. These results compared favorably with 
historic results from the same authors when they used standard 
balloon dilation. Notably, no major complications occurred with 
this approach.
Maintained Large-Bore Catheter
A different approach proposed to enhance the patency rate of 
percutaneous treatment of BBSs involves the use of large-bore 
Figure 1: Intraprocedural three-dimensional reconstructed cone-beam CT images show occlusion of the 
right posterior hepatic duct; however, posterior ducts were communicating with caudate lobe ducts. Per-
cutaneous reconstruction was not possible because of the acute angle of the reconstruction path. Surgical 
biliary enteric anastomosis was performed by using caudate lobe ducts.
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of polydioxanone, a material often used to make surgical sutures; 
this material degrades over approximately 3–6 months via a hy-
drolytic process. Biodegradable stents, which are currently under 
evaluation in Europe for “CE marking” (a certification mark 
that indicates conformity to standards for products sold within 
the European Economic Area), can be provided to patients only 
as custom-made devices; the stents must be manufactured on a 
patient-by-patient basis in the desired size and length. Because 
polydioxanone is radiolucent, these stents include two platinum 
markers at the extremities to make them visible on radiographs. 
In a recent multicenter study (58), 107 patients underwent bio-
degradable stent implantation to treat BBS refractory to stan-
dard bilioplasty. In this series, stricture recurrence occurred in 
18% of the 97 patients with at least 6 months of follow-up, with 
an estimated mean time to stricture recurrence of 38 months. 
The estimated stricture recurrence rates were 7.2%, 26.4%, and 
29.4% at 1, 2, and 3 years, respectively. Notably, because these 
stents are absorbed by the body, no further invasive procedures 
(such as those needed for catheter exchange or stent removal) 
are necessary after implantation, and patients are generally dis-
charged without any external access to the biliary system. Thus, 
biodegradable stents may represent an interesting treatment op-
tion for BBS, potentially offering not only better technical re-
sults but also a better quality of life for patients thanks to the 
reduced invasiveness of this strategy (59) (Fig 4).
Intraprocedural imaging and guidance tools, such as cone-
beam CT, have revolutionized the management of challenging 
almost occlusive or occlusive biliary strictures that are not other-
wise surgical candidates. These tools can increase the operator’s 
confidence in performing complex procedures, such as percuta-
neous recanalization of occluded hepaticojejunostomy, that are 
complex and risky due to the proximity of biliary ducts to major 
vascular structures, such as the portal vein (15) (Fig 5).
Management of MBSs
The stage of MBS determines whether the patient is a can-
didate for curative surgical resection or less invasive palliative 
therapy and is determined according to the extent of local inva-
sion and the presence of distant disease.
Medical and Surgical Options
Candidacy for medical and surgical treatment options should 
be considered before minimally invasive palliative options are 
implemented. Temporary options for biliary decompression are 
more appropriate than permanent options if timely resolution 
of MBO is predicted with medical management. For example, 
MBO caused by lymphoma or metastatic lymphadenopathy 
and are equipped with a couple of drawstrings attached to the 
upper margin of the stent for subsequent removal (52,53). Un-
covered stents are not recommended in the treatment of BBS, 
as epithelization and ingrowth might occur, making removal 
impossible. In a series of 68 patients who underwent CSEMS 
placement, Gwon et al (52) reported clinical success in 59 
(86.8%) patients. In their series, stent migration occurred in 
16.2% of patients, and 20% of patients experienced restenosis 
at follow-up (mean, 36 months). The mean indwelling period 
of the drainage catheter in this series was 5.8 months. In an-
other series of 79 patients with BBS treated with CSEMSs, 
Kahaleh et al (54) reported that 90% of patients had resolu-
tion of strictures and 14% had stent migration at a median of 
12 months. In preliminary reports from a large prospective 
multinational study of 187 patients with BBS treated with 
CSEMSs, removal success after an extended indwelling period 
(range, 10–12 months) and stricture resolution was observed 
in approximately 75% of patients, and serious adverse events 
related to the stent or its removal occurred in 27.3% of patients 
(55). These studies offer some promising results but highlight 
that there are still substantial problems to overcome, such as 
relatively high stent migration and complication rates.
Use of biodegradable stents has been proposed to treat BBS 
refractory to standard bilioplasty (56,57). These stents are made 
Table 3: Diagnostic Imaging of Biliary Obstruction
Modality
Sensitivity for Detection  
of Obstruction (%)
Specificity for Classification  
as Benign or Malignant (%)
Accuracy in Determining  
Extent of Stricture (%) Reference No.
US 90–95 30–70 Low* 10
CT .90 60–90 75 10, 18
MRI or MR cholangiopancreatography 95–98 30–90 88–96 11, 17–20
* No published data, as US is inferior to cross-sectional imaging in the complete evaluation of the biliary tree.
Figure 2: Fluoroscopic percutaneous transhepatic chol-
angiographic image shows extensive multifocal intra- and 
extrahepatic biliary strictures (arrows) due to intrahepatic 
cholangiocarcinoma.
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surgical excision of hilar 
cholangiocarcinoma. A 
total of 287 PTBD cath-
eters were placed in 133 
patients who underwent 
resection, and the suc-
cess rate to relieve jaun-
dice (bilirubin level ,2 
mg/dL [34.2 mmol/L]) 
was 100%. Similarly, 
research has shown that 
aggressive resection of 
hepatocellular carci-
noma in conjunction 
with interval portal vein 
embolization, thermal 
ablation, chemoembo-
lization, and temporary 
biliary drainage for bili-
ary obstruction is asso-
ciated with improved 
survival when compared 
with minimally invasive 




The most common ap-
plication of minimally 
invasive biliary drainage of MBO is palliation of symptoms in 
patients who are unable to undergo resection. However, this 
technique is also used for preoperative drainage before cura-
tive resection. This indication is controversial, as published 
reports provide contradictory evidence regarding its benefits 
and risks. Preoperative drainage is standard practice in the 
setting of infectious cholangitis, and it is routinely used to 
prevent atrophy of the affected liver in patients who require 
a long interval before surgical resection (65). However, in the 
absence of signs of infection, preoperative instrumentation 
of the biliary tree carries a theoretical risk of postoperative 
wound infection and infectious cholangitis (66). Several stud-
ies have shown either no improvement in surgical morbidity 
and mortality after preoperative drainage (67,68) or an actual 
increase in infection-related surgical morbidity (63,69,70). In 
contradistinction, other published reports support the use of 
preoperative biliary drainage. A retrospective review of 82 pa-
tients who underwent resection of ampullary carcinoma dem-
onstrated a marked reduction in wound infection in patients 
who underwent preoperative drainage versus those who un-
derwent no preoperative drainage (2.9% vs 25.5%, P = .01) 
(71). The groups were otherwise matched for infectious risk 
factors and survival rates. For patients undergoing pancreatic 
head resection, routine preoperative biliary drainage has been 
associated with reduced perioperative bacteremia and bleed-
ing (72), reduced postoperative hospitalization, and reduced 
postoperative morbidity (73).
may resolve with chemotherapy and supportive care, without 
the need for invasive therapies (60). In such patients, manage-
ment options might include plastic stents, retrievable covered 
metal stents, and internal or external biliary drainage catheters.
When clinicians are considering options for curative resec-
tion, aggressive surgical strategies developed in the past few 
decades may be better options than palliative drainage. For 
example, aggressive resection of hilar cholangiocarcinoma 
in conjunction with temporary biliary drainage and interval 
portal vein embolization has been associated with improved 
survival when compared with minimally invasive drainage op-
tions and chemotherapy only (61–63). In a study by Kosuge 
et al (61), biliary decompression was performed in 70.8% of 
the patients before surgical resection; 87.0% of these patients 
underwent PTBD. Preoperative portal vein embolization was 
performed in all patients (100%) who underwent left triseg-
mentectomy, in 78.9% of patients who underwent extended 
right hepatectomy, and in 9.7% of patients who underwent 
extended left hepatectomy. Mean and median survival in pa-
tients who underwent surgical resection were 73.6 and 28.0 
months, respectively. In patients who underwent surgical re-
section, 1-, 5-, and 10-year survival rates were 78.2%, 32.8%, 
and 26.2%, respectively. In contrast, most of the patients 
who did not undergo surgical resection died within 2 years. 
In another study by Nimura et al (62), multiple uni- or bilat-
eral preoperative PTBD procedures were performed to relieve 
jaundice in 133 (94%) of the 142 patients who underwent 
Figure 3: US images show the process used for US-
guided access to a left-sided dilated biliary duct. (a) 
Left-sided dilated biliary duct (∗). (b) US-guided punc-
ture of the bile duct (∗) with a small 21-guage needle 
(arrowheads). (c) US-guided insertion of a guidewire 
(arrowhead) into the bile duct (∗).
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endoscopic cannulation, and the PTBD group also required 
fewer subsequent interventions.
Success and route of biliary drainage.—In most patients 
and depending on local practice, EBD tends to be the first 
choice over PTBD when EBD is anatomically feasible, as us-
ing the endoscopic pathway avoids the discomfort and poten-
tial complications of external catheters, such as dislodgment 
PTBD may be preferable to endoscopic biliary drainage 
(EBD) for preoperative drainage. An observational study of 
115 patients undergoing resection of hilar cholangiocarcinoma 
compared preoperative EBD with PTBD. The technical success 
rates were 81% and 100%, respectively (P = .20), and infectious 
complications occurred in 48% and 9% of patients, respectively 
(P , .05) (74). PTBD enabled successful salvage of all patients 
with failed EBD (n = 30), including nine with failed initial 
Figure 4: Percutaneous cholangiographic images in an 83-year-old-woman who underwent pancreaticoduo-
denectomy for carcinoma in the pancreas and who had recurrent benign biliary stricture at the site of hepatico-
jejunostomy. She underwent percutaneous biliary drainage and balloon dilation and received a biodegradable 
biliary stent. (a) Dilated intrahepatic biliary tree and almost-occlusive stricture of the bilioenteric anastomosis 
(arrow). (b) Placement of a percutaneous biliary drainage catheter (arrowheads) crossing the biliary stricture 
(arrow), with subsequent contrast opacification of a bowel loop. (c) Balloon (arrowhead) dilation of the stenosis 
(arrow). (d) Resolution of the stricture after placement of a biodegradable biliary stent (arrowheads) indicate 
platinum markers at the ends of the stent.
Kapoor et al
Radiology: Volume 289: Number 3—December 2018  n  radiology.rsna.org 597
involving 301 patients found that therapeutic success with this 
technique was 63.55% (95% confidence interval: 53.7%, 72.86%) 
(28). Hilar cholangiocarcinoma is often considered an exception to 
this rule, as reports have demonstrated higher technical and clinical 
success rates for PTBD than for EBD in such patients. In a study 
by Lee et al (76) comparing endoscopic retrograde biliary drain-
age, external PTBD, and internal biliary stent placement via the 
(66,75). In general, PTBD is usually reserved for patients with 
failed or infeasible EBD, although this practice varies depend-
ing on the patient and local expertise, and both techniques re-
main common options for all levels of obstruction. The use of 
double-balloon endoscopy for therapeutic EBD in the setting 
of altered anatomy, such as Roux-en-Y hepaticojejunostomy, 
has reduced the need for PTBD; a meta-analysis of 10 studies 
Figure 5: Images in a 34-year-old man with a history of congenital biliary atresia who had previously undergone left hepatic lobectomy and 
the Kasai procedure and who reported repeated episodes of acute cholangitis. US revealed intrahepatic biliary duct dilatation. Percutaneous tran-
shepatic cholangiography and biliary drainage were performed, and percutaneous reconstruction of the biliary-enteric anastomosis was planned. 
(a) Percutaneous cholangiogram shows markedly irregular intrahepatic biliary ducts that are compatible with changes consistent with chronic 
cholangitis. There is an occlusive stricture at the site of hepaticojejunostomy (arrow). (b) Fusion of an intraprocedural unenhanced cone-beam CT 
image with prior contrast-enhanced CT images and drawing of the biliary-enteric anastomosis reconstruction path using intraprocedural guidance 
system software. (c) Fluoroscopic image shows outline of the portal vein (arrow) and biliary-enteric anastomosis reconstruction path (arrowhead) 
superimposed over a fluoroscopic image. (d) Percutaneous access into the jejunal loop across occluded hepaticojejunostomy. Sharp recanaliza-
tion of occluded hepaticojejunostomy was performed by using a pediatric transhepatic portosystemic shunt needle (Cook, Bloomington, Ind). Con-
trast enhancement is seen in the jejunal loop. (e) Cholangiogram shows placement of a 12-F internal-external biliary drainage catheter. (f) Sheath 
cholangiogram at 13-month follow-up shows widely patent hepaticojejunostomy. Biliary catheter was removed. (Reprinted, with permission, from 
reference 121.)
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with abnormal coagulation parameters, those with cirrhosis, and 
those with damage to a large portal branch. Thus, it is important 
to access the peripheral biliary system.
Arterial injury is uncommon in these patients. When arte-
rial injury does occur, it manifests as severe pulsatile bright red 
bleeding, continuous slowly decreasing hematocrit levels (or an 
acute large decrease), or melena. Another clue to arterial bleed 
ing is leakage of bright red blood around rather than through 
the catheter. In these cases, arteriography should be performed, 
and embolization of the bleeding artery should be performed at 
the hepatic artery pseudoaneurysm or active extravasation site.
Potential major complications unique to EBD include 
bowel perforation and bleeding from sphincterotomy and from 
sharp transgastric and transduodenal puncture techniques. 
Pancreatitis can result from distention of the pancreatic duct 
due to contrast material, injury, or obstruction by sludge, 
stones, or stents. In patients with MBO, the risk of pancreatitis 
is less than 5% after PTBD but can exceed 15% after EBD 
(26,85). When external catheter drainage is necessary because 
of failed internal access, short- and long-term complications 
include electrolyte abnormalities and malnutrition. Excessive 
loss of bicarbonate-rich bile can cause orthostatic hypotension, 
prerenal insufficiency, hyponatremia, and a decrease in serum 
bicarbonate level. These abnormalities reverse when catheter 
internalization is achieved; therefore, repeated attempts at 
catheter internalization are warranted and are often successful 
(86). Major complications specific to the placement of metal 
stents are discussed later in this article.
Stent Placement
Self-expanding metal stents (SEMSs)—either uncovered 
SEMS (USEMS), partially covered, or completely CSEMS—
have become standard palliative options in the management 
of MBS because of their ease and accuracy of placement, high 
technical and clinical success rates, and high long-term pa-
tency rates (Fig 6). When compared with SEMSs for MBS, 
plastic stents are more expensive and inconvenient over the 
long term because of their lower long-term patency and the 
need for more endoscopic procedures (87,88). That said, 
plastic stents can serve as a temporary means for decompres-
sion pending biopsy and imaging results that will be used to 
determine clinical management. When clinical management 
centers on palliation, the goal is for stent patency to exceed 
survival to ameliorate symptoms and minimize the need for 
repeat interventions. Plastic stents can be used to achieve this 
goal if the prognosis is poor and expected survival is less than 
3 months (89), but for the most common causes of inoper-
able MBO (pancreatic carcinoma and cholangiocarcinoma), 
SEMSs are more appropriate, as median survival in these pa-
tients ranges from 2 months to 1 year (90–92). For example, 
a retrospective multicenter European study of 240 patients 
yielded 78% and 67% patency rates at 25 weeks for nitinol 
and stainless steel USEMSs, respectively, in a patient popula-
tion with 25- and 50-week survival rates of 42% and 16%, 
respectively (93).
Biliary reconstruction for MBS is best accomplished with 
careful consideration of the anatomic features that may affect the 
PTBD tract (IPTBD), the duration of patency of endoscopic ret-
rograde biliary drainage was comparable to that of IPTBD in Bis-
muth type II and III lesions. On the other hand, this study found 
that stent patency and drainage were statistically superior with 
IPTBD versus endoscopic retrograde biliary drainage for Bismuth 
type IV lesions. In Bismuth type IV lesions, the mean durations 
of patency in patients who underwent IPTBD, endoscopic retro-
grade biliary drainage, and external PTBD were 251 days 6 36 
(standard deviation), 102 days 6 19, and 60 days 6 9, respec-
tively (P , .01). These results can potentially be explained by 
the difficulty in selectively placing a stent in the most optimal 
bile duct in Bismuth type IV lesions while using endoscopic 
retrograde biliary drainage. On the other hand, a meta-analysis 
of 264 screened articles and three randomized controlled tri-
als including 183 patients with cancer found no difference in 
success rates between PTBD and EBD when data collected before 
1990 were excluded (3).
One caveat to the rule of routinely using PTBD to salvage failed 
transpapillary access during EBD is another technique that is now 
available: the use of sharp transgastric, transduodenal, or transhe-
patic puncture of the biliary system with direct endoscopic US 
guidance to bypass the obstructed papilla and place plastic stents 
or covered metal stents across the tract. Reported technical success 
rates in short-term pilot studies of this technique have exceeded 
90% (77–79), but larger series evaluating the safety and clinical 
success of these techniques are not yet available. Future studies 
may identify the best use of sharp EBD, balancing the increased 
risk of bleeding against the improved rate of technical success.
Complications of biliary drainage.—Management of MBO 
with either PTBD or EBD is associated with a higher risk of 
complications than management of benign biliary obstruc-
tion, likely because of the poorer health of these patients (66). 
That said, published data suggest similar 30-day mortality and 
complication rates should be expected for PTBD and EBD in 
the management of MBO (odds ratio, 1.81; 95% confidence 
interval: 0.22, 15.12; P = .583) (3), particularly when the risk 
factors of coagulopathy and ascites are corrected before PTBD 
is performed (66,75,80).
Potential major complications of both PTBD and EBD in-
clude bleeding, biliary sepsis, pancreatitis, and cholecystitis (81). 
In one study, the rates of cholangitis were not significantly differ-
ent between the two techniques (33% for EBD, 22% for PTBD) 
(82). Another study found that the incidence of early cholangitis 
was higher in the EBD group than in the PTBD group (48% 
vs 11%, P = .002); however, the rates of procedure-related mor-
tality were similar in the two groups (PTBD, 4%; ERCP, 8%; 
P = 1.00) (83). A relatively recent study demonstrated an over-
all complication rate of 28%, with no significant difference be-
tween groups (EBD, 29%; PTBD, 25%) (84).
When bleeding occurs after PTBD, the source of bleeding is 
usually a portal vein branch because of its close proximity to one 
of the side holes of the catheter. In such cases, it is usually suffi-
cient to perform cholangiography and adjust the position of the 
side holes. Occasionally, it is necessary to use a bigger catheter. If 
this is a small branch, the bleeding will stop by itself, as the portal 
vein is a low-pressure system; exceptions may be seen in patients 
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the length and location of obstructed ducts that are inaccessible 
for contrast material injection during ERCP. Additional informa-
tion can be obtained from balloon-assisted clearance of sludge and 
debris during stent placement, revealing the true length of the ob-
struction; this step minimizes the length of the stent required and 
the need for extension of the stent across the hilum, cystic duct, or 
outcome. For this reason, percutaneous stent placement should 
be preceded by biopsy and imaging studies, particularly ERCP 
or MR cholangiopancreatography (94), to establish the diagnosis 
of malignancy and to guide stent placement. For patients with 
complete hilar or segmental obstruction, MR cholangiopancrea-
tography offers an added advantage over ERCP in demonstrating 
Figure 6: Images in a 58-year-old man with gradually progressive jaundice. (a) Cholangiographic image 
shows complete occlusion (arrow) of the distal common bile duct (CBD) due to distal CBD cholangiocarcinoma 
and marked dilatation of the CBD and central intrahepatic biliary ducts. (b) Placement of an internal-external bili-
ary drainage catheter. (c) Balloon dilation of the stricture using an 8 3 40-mm balloon. (d) Fluoroscopic image 
shows placement of a 10-mm-diameter partially covered stent graft (Viabil; Gore Medical, Flagstaff, Az) (arrow) 
across the stricture and injection of contrast material, enabling confirmation of a widely patent stent. Good flow 
of contrast material across the stent graft was noted.
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their cost effectiveness in patients with a projected survival of 
less than 12 months. Comparative studies have also failed to 
demonstrate improved survival after CSEMS placement versus 
USEMS placement. For example, a large randomized multi-
center trial of 400 patients with distal MBS demonstrated no 
significant difference in patency in or survival of patients under-
going either CSEMS or USEMS placement (109). In addition, 
a meta-analysis of 13 studies involving 2239 patients undergoing 
either USEMS or CSEMS placement demonstrated no statisti-
cally significant survival benefit with CSEMSs (110). On the 
other hand, in a prospective randomized trial of MBO caused 
by pancreatic cancer, 80 patients underwent either CSEMS or 
USEMS placement; mean patency was 234 days for CSEMS 
placement and 166 days for USEMS placement (P = .007), and 
median survival was 247 and 203.2 days, respectively (P = .06) 
(111). Because survival and stent patency were longer in the 
CSEMS group, the cost per survival day in the CSEMS group 
was comparable to that in the USEMS group.
Complications of Metal Stents for MBS
Complications of metal stents for MBS include bleeding, chol-
angitis, cholecystitis, pancreatitis, stent migration, and obstruc-
tion (109). CSEMSs migrate and obstruct side branches more 
frequently than do USEMSs. Some manufacturers have added 
features, such as flared ends, barbs, and partial coverings, to reduce 
such complications. Bleeding risk is more closely related to the 
point of biliary access during the initial PTBD than to the type of 
SEMS and placement technique. In a retrospective study of 446 
patients analyzed with multivariate logistic regression, bleeding 
risk was progressively reduced by accessing more peripheral ducts, 
from lobar to segmental to subsegmental (112). That said, bleed-
ing risk is exacerbated by overzealous poststent placement dilata-
tion, which is not necessary, as SEMSs continue to expand after 
placement. Dilatation after stent placement can result in lacera-
tion of the tumor and bleeding from the tumor vascularity. Con-
servative balloon sizing and avoidance of poststent dilatation may 
minimize the risk of this complication (109).
Cholangitis is the most common infectious complication of 
stent placement, and so the use of periprocedural antibiotics is 
recommended in all patients (66). Fever and leukocytosis usually 
resolve with intravenous antibiotics and, if percutaneous catheter 
access has been maintained, with delayed fluoroscopically guided 
balloon-assisted clearance of clots and debris. Cholangitis after 
stent placement is less common with percutaneous stent place-
ment than with endoscopic stent placement (113), possibly be-
cause of the rapid duct decompression and the short interval of 
internal-external catheter placement associated with the percuta-
neous approach. In a meta-analysis of 13 studies involving 2239 
patients with MBO, there was no significant difference in the 
overall adverse event rate with CSEMSs versus USEMSs; how-
ever, CSEMSs seemed to have significantly lower occlusion rates, 
increased odds of migration, and an increased risk of pancreatitis 
compared with USEMSs (110). Other studies have shown similar 
rates of pancreatitis and cholecystitis after CSEMS and USEMS 
placement (66,108). Pancreatitis after stent placement is usually 
caused by contrast material injection into the pancreatic duct and 
is not affected by the choice of a CSEMS or USEMS (114). Acute 
papilla, thereby minimizing the risks of recurrent biliary obstruc-
tion, cholecystitis, and pancreatitis, respectively.
For obstruction of the hilum and proximal common bile 
duct, avoiding stent placement across the papilla has been shown 
to improve long-term patency and to reduce the risk of ascending 
cholangitis (95,96) and pancreatitis (97). Placement of SEMSs 
across the papilla in patients with hilar obstruction is controver-
sial. A retrospective review of 172 patients who underwent either 
trans- or suprapapillary SEMS placement for hilar MBS showed 
no difference in success rates, stent patency duration, or stent 
occlusion rates (97).
When SEMSs are placed via a percutaneous approach, a 1- 
to 2-week period of internal-external biliary drain placement 
allows for easy interval management of complications, such 
as bleeding and acute reobstruction. This option represents 
an advantage of PTBD over EBD, as it provides additional 
opportunities to clear clots and debris and to replace stents in 
problem segments before complete catheter removal.
If possible, stent placement across major branch points should 
be avoided to optimize long-term patency; however, for hilar 
obstruction, MBS involves the confluence of large ducts, and 
two options exist for stent placement: a unilateral USEMS that 
cages the side without a stent or a bilateral Y-configured USEMS 
or CSEMS that extends from the common bile duct to both 
the right and left intrahepatic ducts. In one study, Freeman et 
al (94) observed 77% clinical success and a median patency of 
5.4 months in 35 patients who underwent unilateral USEMS 
placement for hilar biliary obstruction. Other authors have 
achieved similar success with unilateral USEMS and CSEMS 
placement (98) and with Y-configured CSEMS placement (99). 
For hilar obstruction, a USEMS is preferable to a CSEMS if pres-
ervation of the contralateral duct patency is possible (100). Never-
theless, unilateral USEMS placement may result in atrophy of the 
excluded lobe (86); therefore, stent placement into the most viable 
lobe is recommended. The aim should be biliary drainage of more 
than 50% of the liver volume, as this is associated with decreased 
cholangitis after stent placement and increased survival (101).
CSEMSs cost more than USEMSs, which has triggered a 
debate regarding their value and appropriate application in the 
management of MBS. Perhaps the best use of CSEMSs is in pa-
tients with MBS and longer-than-typical predicted survival, as 
reported long-term patency rates for CSEMSs often far exceed 
those of USEMSs for comparable indications of MBS (102–
107). For patients with shorter predicted survival, either option 
would yield sufficient patency, making the lower-cost USEMSs 
more attractive. For example, a meta-analysis of 20 randomized 
controlled trials involving 1713 patients showed no significant 
difference in 6- or 12-month patency rates for USEMSs and 
CSEMSs (108). A related debate centers on whether CSEMSs 
improve survival when compared with USEMSs for comparable 
indications of MBO. A cohort observational study of 80 patients 
who underwent CSEMS placement for MBS showed typically 
low survival rates of 40% and 20.2% at 6 and 12 months, re-
spectively; these rates are comparable to most published rates for 
USEMS placement (104). Furthermore, patency rates of 95.5%, 
92.6%, and 85.7% at 3, 6, and 12 months, respectively, demon-
strate the clinical effectiveness of CSEMSs but call into question 
Kapoor et al
Radiology: Volume 289: Number 3—December 2018  n  radiology.rsna.org 601
References
 1. Zepeda-Gómez S, Baron TH. Benign biliary strictures: current endoscopic 
management. Nat Rev Gastroenterol Hepatol 2011;8(10):573–581.
 2. Fidelman N. Benign biliary strictures: diagnostic evaluation and approaches 
to percutaneous treatment. Tech Vasc Interv Radiol 2015;18(4):210–217.
 3. Leng JJ, Zhang N, Dong JH. Percutaneous transhepatic and endoscopic bili-
ary drainage for malignant biliary tract obstruction: a meta-analysis. World 
J Surg Oncol 2014;12(1):272.
 4. Bismuth H. Postoperative strictures of the bile ducts. In: Blumgart LH, ed. 
The biliary tract, Vol 5. New York, NY: Churchill-Livingstone, 1982; 209–218.
 5. Strasberg SM, Hertl M, Soper NJ. An analysis of the problem of biliary injury 
during laparoscopic cholecystectomy. J Am Coll Surg 1995;180(1):101–125.
 6. Thompson CM, Saad NE, Quazi RR, Darcy MD, Picus DD, Menias CO. 
Management of iatrogenic bile duct injuries: role of the interventional radi-
ologist. RadioGraphics 2013;33(1):117–134.
 7. Shanbhogue AK, Tirumani SH, Prasad SR, Fasih N, McInnes M. Benign 
biliary strictures: a current comprehensive clinical and imaging review. AJR 
Am J Roentgenol 2011;197(2):W295–W306.
 8. Feldman MK, Coppa CP. Noninvasive imaging of the biliary tree for the 
interventional radiologist. Tech Vasc Interv Radiol 2015;18(4):184–196.
 9. Miller FH, Hwang CM, Gabriel H, Goodhartz LA, Omar AJ, Parsons 
WG 3rd. Contrast-enhanced helical CT of choledocholithiasis. AJR Am J 
Roentgenol 2003;181(1):125–130.
 10. Choi SH, Han JK, Lee JM, et al. Differentiating malignant from benign 
common bile duct stricture with multiphasic helical CT. Radiology 
2005;236(1):178–183.
 11. Altman A, Zangan SM. Benign biliary strictures. Semin Intervent Radiol 
2016;33(4):297–306.
 12. Sutter CM, Ryu RK. Percutaneous management of malignant biliary obstruc-
tion. Tech Vasc Interv Radiol 2015;18(4):218–226.
 13. Kim SW, Shin HC, Kim HC, Hong MJ, Kim IY. Diagnostic performance of 
multidetector CT for acute cholangitis: evaluation of a CT scoring method. 
Br J Radiol 2012;85(1014):770–777.
 14. Falkenstein DB, Raicht RF. Direct cholangiography. Semin Liver Dis 
1989;9(1):63–76.
 15. Kapoor BS, Esparaz A, Levitin A, McLennan G, Moon E, Sands M. Non-
vascular and portal vein applications of cone-beam computed tomography: 
current status. Tech Vasc Interv Radiol 2013;16(3):150–160.
 16. Wu XP, Ni JM, Zhang ZY, et al. Preoperative evaluation of malignant perihilar 
biliary obstruction: negative-contrast CT cholangiopancreatography and CT 
angiography versus MRCP and MR angiography. AJR Am J Roentgenol 
2015;205(4):780–788.
 17. Soto JA, Alvarez O, Lopera JE, Múnera F, Restrepo JC, Correa G. Biliary 
obstruction: findings at MR cholangiography and cross-sectional MR imag-
ing. RadioGraphics 2000;20(2):353–366.
 18. Singh A, Gelrud A, Agarwal B. Biliary strictures: diagnostic considerations 
and approach. Gastroenterol Rep (Oxf) 2015;3(1):22–31.
 19. Lee SS, Kim MH, Lee SK, et al. MR cholangiography versus cholangios-
copy for evaluation of longitudinal extension of hilar cholangiocarcinoma. 
Gastrointest Endosc 2002;56(1):25–32.
 20. Fulcher AS, Turner MA. HASTE MR cholangiography in the evaluation of 
hilar cholangiocarcinoma. AJR Am J Roentgenol 1997;169(6):1501–1505.
 21. Corvera CU, Blumgart LH, Akhurst T, et al. 18F-fluorodeoxyglucose posi-
tron emission tomography influences management decisions in patients with 
biliary cancer. J Am Coll Surg 2008;206(1):57–65.
 22. Suthar M, Purohit S, Bhargav V, Goyal P. Role of MRCP in differentiation 
of benign and malignant causes of biliary obstruction. J Clin Diagn Res 
2015;9(11):TC08–TC12.
 23. Xu MM, Sethi A. Diagnosing biliary malignancy. Gastrointest Endosc Clin 
N Am 2015;25(4):677–690.
 24. Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pan-
creatic lesions in asymptomatic high-risk individuals. Gastroenterology 
2012;142(4):796–804; quiz e14–e15.
 25. Shimada H, Endo I, Shimada K, Matsuyama R, Kobayashi N, Kubota K. 
The current diagnosis and treatment of benign biliary stricture. Surg Today 
2012;42(12):1143–1153.
 26. Winick AB, Waybill PN, Venbrux AC. Complications of percutaneous tran-
shepatic biliary interventions. Tech Vasc Interv Radiol 2001;4(3):200–206.
 27. Venkatanarasimha N, Damodharan K, Gogna A, et al. Diagnosis and 
management of complications from percutaneous biliary tract interven-
tions [Published correction appears in RadioGraphics 2017;37(3):1004.] 
RadioGraphics 2017;37(2):665–680.
 28. Shao XD, Qi XS, Guo XZ. Endoscopic retrograde cholangiopancreatography 
with double balloon enteroscope in patients with altered gastrointestinal 
anatomy: a meta-analysis. Saudi J Gastroenterol 2017;23(3):150–160.
cholecystitis after stent placement is almost always caused by cys-
tic duct involvement by the tumor in combination with SEMS 
placement across the cystic duct orifice (115). This complication 
is managed by placement of a percutaneous cholecystostomy cath-
eter that can be removed after resolution of symptoms, a trial of 
catheter capping, and performance of over-the-wire tractography 
to verify tract formation, typically after 4–6 weeks. Demonstration 
of patency of the cystic duct is helpful before catheter removal; 
however, this finding may be unnecessary after a symptom-free 
capping trial and resolution of tube output. In patients with per-
sistent obstruction of the cystic duct and persistent or recurrent 
symptoms of cholecystitis, indefinite external drainage or chemical 
ablation of the gallbladder may be necessary (116).
Acute recurrent obstruction after stent placement may re-
sult from dilatation after stent placement and may lead to ei-
ther hemobilia with obstructive clot formation or extrusion of 
the tumor through the interstices or around the edges of the 
stent. Chronic recurrent obstruction usually results from tumor 
overgrowth at the margins of the SEMS or ingrowth across the 
interstices of the USEMS (76). If survival exceeds patency, repeat 
endoscopic or percutaneous drainage is necessary to replace the 
stent in the tumor progression and to clear debris or stones. If 
extended patency cannot be achieved, placement of a permanent 
internal or external catheter might be required (113).
Palliative treatment of symptoms of inoperable MBO contin-
ues to be the main application of percutaneous and endoscopic 
management. Most practitioners tailor the use of CSEMSs and 
USEMSs on a patient-by-patient basis to provide an option that 
is clinically effective, avoids unnecessary secondary procedures, 
and is cost effective. Because survival rates in patients with MBO 
are limited, existing technologies, such as USEMS and CSEMS, 
yield adequate patency in most patients, and the future appli-
cability of newer strategies hinges on demonstration of a clear 
survival advantage.
Investigational Strategies
Investigational strategies for MBS aim to improve survival and 
patency rates by suppressing local tumor growth. Such strategies 
include intraductal radiofrequency ablation and the placement of 
drug-eluting SEMSs. Pilot studies have demonstrated the safety of 
devices under development for the delivery of intraductal radio-
frequency ablation to improve the long-term patency of SEMSs 
for MBS (117). In addition, limited studies of intraductal radio-
frequency ablation have suggested improvements in patency with 
this method (118,119), although larger series are needed to verify 
the statistical significance. Pilot studies of drug-coated SEMSs for 
MBS have demonstrated improvements over reported patency 
rates for SEMSs, although such studies are underpowered to 
demonstrate improvements in survival. In one multicenter pilot 
study, paclitaxel-encoated SEMSs for MBS had a mean patency of 
429 days (120).
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